Clostridium Difficile News and Research

RSS

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).

6 Dec 2012

Less is more when it comes to antibiotics for UTI in men

Research suggests that standard antibiotic prescribing for urinary tract infections in male patients may need to be reviewed, as currently recommended 7–14-day courses appear to be no more effective than shorter ones, and may increase the risk for antimicrobial resistant or Clostridium difficile infection.

6 Dec 2012

Tissue damage, disease severity in C. diff. infection associated with disruption of PPARγ pathway

Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

1 Dec 2012

Study of hospital-acquired infection yields potential therapeutic target

30 Nov 2012

Eisai announces FDA acceptance of AcipHex NDA for priority review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.

30 Nov 2012

WellStar Health System implements Xenex’s room disinfection system

WellStar Health System was the first to implement and is the only health system in metro-Atlanta using Xenex Healthcare Services' room disinfection system in its patient and operating rooms. A "green," mercury-free technology, the Xenex system is the fastest, safest and most effective method for the advanced cleaning of hospital rooms, scientifically proven to destroy all major classes of microorganisms that cause hospital acquired infections (HAIs), such as MRSA and Clostridium difficile (C. diff).

29 Nov 2012

Abacus Diagnostica’s GenomEra C. difficile assay receives CE mark

Abacus Diagnostica Ltd announced that it has received the CE mark for the GenomEra C. difficile assay for the detection of toxin-producing Clostridium difficile directly from stool samples. C. difficile is the leading cause of infectious nosocomial diarrhea in Europe and North America.

19 Nov 2012

Metalloacid surfaces may be answer to hospital-acquired infections

Coating surfaces in metalloacids may help control the spread of hospital-acquired infections, suggest study findings.

14 Nov 2012

Loyola announces 2012 Junior and Senior Scientist of the Year during St. Albert's Day

Katherine L. Knight, PhD, one of the nation's leading immune system researchers, has been named 2012 Senior Scientist of the Year at Loyola University Chicago Stritch School of Medicine. Sakthivel Sadayappan, PhD, FAHA, who is doing groundbreaking research on a protein that is critical for the normal functioning of the heart, has been named 2012 Junior Scientist of the Year.

7 Nov 2012

Xenex offers room disinfection devices to hospitals hit by Hurricane Sandy

Xenex Healthcare Services, the world leader in UV room disinfection systems, today announced it is making its room disinfection devices available to hospitals affected by Hurricane Sandy.

3 Nov 2012

Researchers figure out 3D shape of promising TB drug target

Researchers at Johns Hopkins have figured out the three-dimensional shape of the protein responsible for creating unique bonds within the cell wall of the bacteria that cause tuberculosis. The bonds make the bacteria resistant to currently available drug therapies, contributing to the alarming rise of these super-bacteria throughout the world.

26 Oct 2012

CUMC researchers develop first true mouse model of typhoid infection

Columbia University Medical Center (CUMC) researchers have created the first true mouse model of typhoid infection. The development promises to advance the study of typhoid and the creation of new vaccines against the infection, which remains a major health threat in developing countries.

26 Oct 2012

New method of oral vaccination could help boost immunity to TB, influenza and C. difficile

Scientists at Royal Holloway, University of London have developed a pioneering new method of oral vaccination which could help boost immunity to TB and influenza, as well as prevent C. difficile for which there is currently no vaccine.

25 Oct 2012

C. diff infections on the rise among children, elderly

Clostridium difficile infections are becoming more common and more severe in hospitalized children and the elderly, in large part due to greater use of antibiotics, Mayo Clinic researchers report in studies being presented at the American College of Gastroenterology annual meeting.

23 Oct 2012

Novel therapy that uses human stool is safe and highly effective in treating C.diff infection

A novel therapy that uses donated human stool to treat the deadly and contagious C.diff infection is safe and highly effective, according to a Henry Ford Hospital study.

20 Oct 2012

Xenex Healthcare Services receives GSA contract to purchase room disinfection systems

Xenex Healthcare Services, the world leader in UV room disinfection systems, today announced it has been awarded a U.S. General Services Administration (GSA) contract, making it even easier for federal agencies (including Veterans Affairs hospital systems) to purchase Xenex's room disinfection systems.

11 Oct 2012

Progress toward preventing initial and recurrent episodes of C. diff infection

Surgeons are making progress toward preventing initial and recurrent episodes of clostridium difficile colitis (C. difficile or C. diff), a vicious bacterial infection that is estimated to affect about 336,000 people each year, typically patients on antibiotics.

6 Oct 2012

TECHLAB to utilize Dynex's Gold SmartKit packaging for ELISA product line

Dynex Technologies, Inc. announced today it has finalized a supply agreement with TECHLAB, Inc. (Blacksburg, VA), allowing TECHLAB to utilize Dynex's Gold SmartKit packaging for their ELISA product line.

20 Sep 2012

New tools can help track healthcare-associated infections in nursing homes

The Society for Healthcare Epidemiology of America (SHEA) and Centers for Disease Control and Prevention (CDC) have each released new tools and information to help track deadly healthcare-associated infections (HAIs) in nursing homes and other long-term care settings.

19 Sep 2012

Xenex's pulsed xenon UV more effective than bleach in decontaminating C. diff surfaces

Healthcare associated infections (also referred to as HAIs or hospital acquired infections) are the fourth leading cause of death in the United States, costing more than $30 billion each year. Evidence continues to mount that hospital cleanliness plays a role in the spread of HAIs, which are caused by deadly pathogens such as C. diff, MRSA, VRE and Acinetobacter.

19 Sep 2012